How do you pay?

How to pay the least

Ask for the cash price

Wezlana

Wezlana is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Wezlana’s cash price, and one or two other pharmacies too.
  2. Wezlana’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameWezlana
Authorized genericustekinumab-auub
Regular genericustekinumab-auub
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Wezlana?
The original
–
–

Brand nameThe maker’s card

WEZLANA Co-Pay Program

Savings card from Nuvaila

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

Sign up on wezlana.com 

Or call 1-833-442-6436.

In the maker’s words

“Pay as little as $0 out-of-pocket for each dose…”

From the maker’s offer on wezlana.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Wezlana itself, from the same company, sold without the brand name, and usually for less. For now Wezlana is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Wezlana is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

WEZLANA is a human interleukin -12 and -23 antagonist indicated for the treatment of:

  • Moderate to severe plaque psoriasis in adult and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy.
  • Active psoriatic arthritis in adult and pediatric patients 6 years of age and older.
  • Moderately to severely active Crohn's disease in adult patients.
  • Moderately to severely active ulcerative colitis in adult patients.

Source: the FDA label for Wezlana (Nuvaila Limited), June 3, 2026. Full label on DailyMed 

Good to know